Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC

NCT03175705 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: HCC antigens-specific CD8+ T lymphocytes
DRUG: IL-2
DRUG: Tegafur

Sponsor

Beijing YouAn Hospital